Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | CCKBR | P32239 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19203559 | 0.89 | MEN1 (0.61) | MEN1KMT2ACTSLCTSSCTSK | |
| SCHEMBL19203560 | 0.81 | MEN1 (0.48) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL6160782 | 0.81 | MEN1 (0.73) | MEN1KMT2ACTSLCTSSCTSK | |
| SCHEMBL6162223 | 0.81 | MEN1 (0.73) | MEN1KMT2ACTSLCTSSCTSK | |
| SCHEMBL22054522 | 0.78 | MEN1 (0.45) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL22054531 | 0.77 | MEN1 (0.45) | MEN1KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL19203445 | 0.74 | CTSL (0.65) | CTSLCTSSCTSKCCKBRTP53 | |
| SCHEMBL4904222 | 0.74 | CTSL (0.49) | MEN1KMT2ACTSLCTSSCTSK | |
| SCHEMBL6164208 | 0.72 | MEN1 (0.58) | MEN1KMT2ACTSLHDAC3HDAC4 | |
| SCHEMBL6164202 | 0.72 | MEN1 (0.58) | MEN1KMT2ACTSLHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2021-08-19 | — | — | US | disclosed |
| US-20200172572-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ALLERGAN GI CORP (US) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253634-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | MEN1 182/4885KMT2A 3727/4885CTSL 1982/4885 |
| US-20200172572-A1 | PROCESS FOR THE LIQUID PHASE SYNTHESIS OF H-INP-(D)BAL-(D)TRP-PHE-APC-NH2, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VIP, IAPP, PROKR1 | MEN1 182/4885KMT2A 3727/4885CTSL 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.